The Pharma Letter

The Pharma Letter offers precise and impartial business insights into the global pharmaceutical, generic, and biotechnology sectors. Countless professionals in these fields rely on The Pharma Letter to stay informed about the latest news and developments, ensuring they are always ahead in making critical business decisions. The content is crafted while the news is still fresh, maximizing its relevance and impact. You can save time and energy by receiving trustworthy, analyzed, and unbiased news delivered online to your screen each day. Additionally, you'll get email alerts and complete access to The Pharma Letter's searchable archive dating back to 1991.

International, Trade/B2B

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#558015

United States

#288595

Health/Pharmacy

#549

Traffic sources

Monthly visitors

Articles

UNITY Biotechnology tanks on mixed results for eye disease drug | The Pharmaletter

2 months ago | thepharmaletter.com

California, USA-based UNITY Biotechnology (Nasdaq: UBX] has announced top-line results from the Phase IIb ASPIRE clinical trial of intravitreal UBX1325 (foselutoclax) in patients with diabetic macular edema (DME) who had poor vision despite prior anti-VEGF treatment.
No Title

2 months ago | thepharmaletter.com
Hexaell Biotech advances liver program with $31 million raise | Biotechnology | The Pharmaletter | The Pharmaletter

Mar 8, 2025 | thepharmaletter.com

Shanghai-based biotech firm Hexaell Biotech has secured 200 million renminbi ($31 million) in a series B+ funding round. The investment was led by Shanghai Biomedical Fund, with continued support from existing backer Longpan Investment and participation from Guanghua Wutong.
No Title

Mar 8, 2025 | thepharmaletter.com
No Title

Feb 7, 2025 | thepharmaletter.com
No Title

Feb 5, 2025 | thepharmaletter.com
Mid-stage hit for novel lung cancer drug zipalertinib | Pharmaceutical | The Pharmaletter | The Pharmaletter

Jan 30, 2025 | thepharmaletter.com

Cullinan Therapeutics and its partner Taiho Pharmaceutical have reported a win for zipalertinib, with the primary endpoint of a Phase IIb trial being met. The data, which include a positive safety profile, set the stage for a potential submission to the US Food and Drug Administration in the second half of 2025.
Latin America's major 2025 challenges for securing population-wide access to innovative medicines

Jan 16, 2025 | thepharmaletter.com | Ángel Galindo

Despite the strategies and programs that have been implemented to bring effective and equitable access to new medicines and technologies that provide equal or similar opportunities for citizens, regardless of their country, the reality is very different in Latin America, writes The Pharma Letter's local correspondent.
With tislelizumab, BeiGene brings immunotherapy to more patients in Europe

Jan 16, 2025 | thepharmaletter.com | Guy Martin

This executive interview, sponsored by BeiGene (Nasdaq: BGNE; HKEX: 06160; SSE: 688235), is with Jan-Henrik Terwey, Vice President, Medical Affairs Europe at BeiGene. Almost every week brings news on the progress of tislelizumab, BeiGene’s (Nasdaq: BGNE) uniquely designed humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1.
ASH 2024: Hematologists ready for big showcase

Dec 1, 2024 | thepharmaletter.com | Guy Martin

Privacy Policy When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies.